GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumors, reported financial results for the quarter ended June 30, 2026, and provided a business update highlighting continued progress toward the planned initiation of its pivotal GEO-MVA immunobridging study under an expedited regulatory pathway, while also advancing its Gedeptin immuno-oncology program.
During the second quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study under the expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA). These activities included continued clinical study readiness, manufacturing preparedness, and stakeholder engagement.
"During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense."
GeoVax continued operational activities in advance of the planned study initiation, including clinical operations planning, utilization of previously manufactured cGMP clinical trial material, advancement of the AGE1 continuous cell-line manufacturing platform for future commercial-scale production, and engagement with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements. The company believes GEO-MVA is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity.
In oncology, GeoVax continues advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy, toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies, such as Merck's Keytruda, by improving responsiveness in immunologically resistant tumors. GeoVax continues to strengthen the program's strategic positioning through its exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578 for the quarter ended June 30, 2026, or $0.97 per share, compared to a net loss of $5,369,783, or $8.74 per share, for the same period in 2025. The company reported no revenue from government contracts in the 2026 period, compared to $852,282 in the prior year period, due to the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program in April 2025. Research and development expenses decreased to $3,110,508 from $4,728,998, primarily reflecting lower costs associated with discontinued BARDA activities and reduced spending on GEO-CM04S1. General and administrative expenses decreased to $1,331,564 from $1,542,190, mainly due to lower investor relations consulting costs and reduced stock-based compensation. As of June 30, 2026, the company reported cash balances of approximately $3.1 million.
GeoVax's strategic priorities include execution of the GEO-MVA pivotal immunobridging clinical program, advancement of scalable continuous cell-line manufacturing capabilities, engagement supporting future government and international procurement opportunities, advancement of Gedeptin combination immunotherapy strategies, and disciplined capital deployment.
For more information, visit www.geovax.com.
